NVG 111
Alternative Names: NVG-111Latest Information Update: 13 Dec 2023
Price :
$50 *
At a glance
- Originator NovalGen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Preclinical Malignant melanoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma
Most Recent Events
- 11 Dec 2023 Efficacy data from a phase I/II trial in Chronic lymphocytic leukaemia and Mantle-cell lymphoma released by NovelGen
- 10 Dec 2023 Adverse events and pharmacodynamics data from preclinical studies in Cancer presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Chronic lymphocytic leukemia and Mantle cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)